Emmaus Life Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EMMA research report →
Price Chart
About the company
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations.
- CEO
- Willis C. Lee
- IPO
- 2000
- Employees
- 33
- HQ
- Torrance, CA, US
Get TickerSpark's AI analysis on EMMA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.25M
- P/E
- -0.25
- PEG
- 0.01
- P/S
- 0.16
- P/B
- -0.03
- EV/EBITDA
- 12.19
- Div Yield
- 0.00%
- Gross Margin
- 92.05%
- Op Margin
- 24.81%
- Net Margin
- -61.87%
- ROE
- 13.05%
- ROIC
- -13.31%
Latest fiscal year · YoY change
- Revenue
- $12.45M-25.2%
- Gross Profit
- $11.60M-25.0%
- Op Income
- $231.00K
- Net Income
- $-7,492,000-16.1%
- EPS
- $-0.12-20.0%
- OCF Growth
- +99.5%
- FCF Growth
- +99.5%
- 52W High
- $0.09
- 52W Low
- $0.01
- 50D MA
- $0.05
- 200D MA
- $0.02
- Beta
- 9.77
- RSI (14)
- 48
- Avg Volume
- 63.26K
No earnings-call transcripts are available for EMMA yet.
- Free Float
- 51.3%
- Shares Outstanding
- 70.19M
- Float Shares
- 35.98M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 31, 26 | LEE WILLIS C | buy | 100,000 |
| Aug 28, 26 | LEE WILLIS C | buy | 94,767 |
| Aug 27, 26 | LEE WILLIS C | buy | 50,000 |
| Aug 25, 26 | LEE WILLIS C | buy | 46,000 |
| Aug 29, 25 | LEE WILLIS C | buy | 170,000 |
| May 30, 25 | LEE WILLIS C | buy | 70,000 |
| Apr 16, 26 | DU HENRY HUY | other | 0 |
| Oct 1, 24 | Kuwahara Jon | other | 0 |
| Sep 16, 24 | Lim Seah H. | buy | 20,000 |
| Feb 29, 24 | LEE WILLIS C | buy | 77,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EMMA coverage
Recent articles, reports, and earnings notes.
No research on EMMA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EMMA report →Emmaus Life Sciences Reports Quarterly Financial Results
gurufocus.com · Nov 18
Emmaus Life Sciences Reports Quarterly Financial Results
businesswire.com · Nov 18
Emmaus Life Sciences Advances Middle East Strategy with Real-World Evidence Initiatives and Expansion into Africa
businesswire.com · Nov 12
Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer
businesswire.com · Aug 31
Emmaus Life Sciences Reports Quarterly Financial Results
businesswire.com · Aug 14
Emmaus Life Sciences Reports Quarterly Financial Results
gurufocus.com · May 15
Emmaus Life Sciences Reports Quarterly Financial Results
businesswire.com · May 15
Emmaus Life Sciences Reports Annual Financial Results
businesswire.com · Mar 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.